Oppenheimer & Co. Inc. Sells 22,124 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Oppenheimer & Co. Inc. trimmed its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 68.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,278 shares of the company's stock after selling 22,124 shares during the period. Oppenheimer & Co. Inc.'s holdings in Teva Pharmaceutical Industries were worth $227,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in TEVA. FMR LLC grew its stake in Teva Pharmaceutical Industries by 49.5% in the 3rd quarter. FMR LLC now owns 62,740,763 shares of the company's stock worth $1,130,589,000 after acquiring an additional 20,762,226 shares in the last quarter. Janus Henderson Group PLC grew its stake in Teva Pharmaceutical Industries by 7,945.2% in the 3rd quarter. Janus Henderson Group PLC now owns 4,791,937 shares of the company's stock worth $86,350,000 after acquiring an additional 4,732,374 shares in the last quarter. Todd Asset Management LLC bought a new position in Teva Pharmaceutical Industries in the 4th quarter worth about $58,243,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Teva Pharmaceutical Industries by 237.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,377,517 shares of the company's stock worth $60,863,000 after acquiring an additional 2,376,668 shares in the last quarter. Finally, Clal Insurance Enterprises Holdings Ltd grew its stake in Teva Pharmaceutical Industries by 6.8% in the 3rd quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company's stock worth $621,337,000 after acquiring an additional 2,204,623 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Trading Down 0.1 %

NYSE:TEVA opened at $15.34 on Monday. Teva Pharmaceutical Industries Limited has a 52 week low of $12.51 and a 52 week high of $22.80. The firm has a 50 day moving average of $18.85 and a 200 day moving average of $18.38. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The stock has a market capitalization of $17.40 billion, a price-to-earnings ratio of -10.58, a PEG ratio of 1.44 and a beta of 0.82.

Remove Ads

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the company's stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. This represents a 29.15 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.55% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Bank of America dropped their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research note on Thursday. Piper Sandler upped their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, January 17th. StockNews.com cut shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research report on Friday. Barclays lowered their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, January 30th. Finally, UBS Group lowered their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $23.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.